A Gómez Villanueva Selected Research

ErbB Receptors (EGF Receptor)

1/2019

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

A Gómez Villanueva Research Topics

Disease

1	Breast Neoplasms (Breast Cancer) 01/2019
1	Exanthema (Rash) 01/2019

Drug/Important Bio-Agent (IBA)

1	capivasertibIBA 01/2019
1	Peptides (Polypeptides)IBA 01/2019
1	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2019
1	Estrogen ReceptorsIBA 01/2019
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2019
1	Protein Isoforms (Isoforms)IBA 01/2019
1	ErbB Receptors (EGF Receptor)IBA 01/2019